Your browser is no longer supported. Please, upgrade your browser.
Settings
LMNL [NASD]
Liminal BioSciences Inc.
Index- P/E0.26 EPS (ttm)20.00 Insider Own67.67% Shs Outstand23.59M Perf Week-8.77%
Market Cap147.29M Forward P/E- EPS next Y-0.72 Insider Trans0.00% Shs Float9.50M Perf Month3.24%
Income-93.10M PEG- EPS next Q-0.59 Inst Own6.80% Short Float1.88% Perf Quarter-10.68%
Sales2.60M P/S56.65 EPS this Y93.90% Inst Trans-37.63% Short Ratio0.12 Perf Half Y-52.78%
Book/sh1.21 P/B4.21 EPS next Y74.30% ROA- Target Price- Perf Year-54.50%
Cash/sh0.99 P/C5.17 EPS next 5Y- ROE- 52W Range3.51 - 31.45 Perf YTD21.43%
Dividend- P/FCF- EPS past 5Y-27.80% ROI-149.20% 52W High-83.78% Beta1.85
Dividend %- Quick Ratio1.80 Sales past 5Y-26.60% Gross Margin36.50% 52W Low45.30% ATR0.49
Employees300 Current Ratio2.20 Sales Q/Q-25.00% Oper. Margin- RSI (14)54.24 Volatility7.22% 8.78%
OptionableNo Debt/Eq2.10 EPS Q/Q22.70% Profit Margin- Rel Volume0.26 Prev Close5.15
ShortableYes LT Debt/Eq1.89 Earnings- Payout- Avg Volume1.44M Price5.10
Recom2.70 SMA207.56% SMA5013.42% SMA200-43.40% Volume373,509 Change-0.97%
Dec-21-20Initiated Piper Sandler Overweight $22
Jan-21-21 08:30AM  
Jan-12-21 09:00AM  
09:00AM  
Jan-06-21 09:55AM  
Dec-15-20 09:20AM  
09:20AM  
Dec-11-20 11:11AM  
Dec-01-20 08:00AM  
Nov-13-20 09:20AM  
Nov-12-20 04:57PM  
04:57PM  
Nov-10-20 06:33PM  
06:33PM  
Nov-08-20 07:01PM  
Nov-06-20 09:26AM  
Nov-05-20 04:35AM  
04:35AM  
Oct-30-20 08:30AM  
08:30AM  
Oct-07-20 09:30AM  
Sep-21-20 08:16AM  
08:16AM  
Sep-09-20 08:00AM  
Sep-08-20 06:00AM  
Sep-01-20 08:36AM  
08:36AM  
Aug-25-20 08:49AM  
Aug-24-20 01:30PM  
10:03AM  
Aug-10-20 05:01PM  
Aug-06-20 05:01PM  
Jul-22-20 07:55AM  
Jul-17-20 08:00AM  
Jul-02-20 11:16AM  
Jun-30-20 05:31PM  
05:31PM  
05:00PM  
05:00PM  
Jun-11-20 05:00PM  
Jun-09-20 03:53PM  
03:53PM  
May-28-20 05:30PM  
May-22-20 07:14AM  
May-13-20 05:00PM  
Mar-23-20 06:30AM  
Mar-22-20 03:23PM  
03:23PM  
Mar-20-20 05:01PM  
05:01PM  
05:00PM  
Feb-12-20 07:30AM  
07:30AM  
Feb-06-20 07:30AM  
Jan-13-20 07:00AM  
07:00AM  
Dec-23-19 03:43PM  
Nov-28-19 04:40PM  
04:40PM  
Nov-27-19 07:30AM  
Nov-25-19 12:03PM  
Nov-18-19 07:30AM  
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel treatments for patients suffering from diseases that have unmet medical needs. It operates through two segments, Small Molecule Therapeutics and Plasma Derived Therapeutics. The Small Molecule Therapeutics segment's lead product candidate is fezagepras (PBI-4050) for the treatment of idiopathic pulmonary fibrosis, respiratory diseases, and Alstrom Syndrome. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The company operates in Canada, the United Kingdom, and the United States. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.